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Achieving high coverage in Rwanda’s national human papillomavirus
vaccination programme
Agnes Binagwaho,a Claire M Wagner,b Maurice Gatera,c Corine Karema,c Cameron T Nuttd & Fidele Ngaboa
Problem Virtually all women who have cervical cancer are infected with the human papillomavirus (HPV). Of the 275 000 women who die
from cervical cancer every year, 88% live in developing countries. Two vaccines against the HPV have been approved. However, vaccine
implementation in low-income countries tends to lag behind implementation in high-income countries by 15 to 20 years.
Approach In 2011, Rwanda’s Ministry of Health partnered with Merck to offer the Gardasil HPV vaccine to all girls of appropriate age. The
Ministry formed a “public–private community partnership” to ensure effective and equitable delivery.
Local setting Thanks to a strong national focus on health systems strengthening, more than 90% of all Rwandan infants aged 12–23 months
receive all basic immunizations recommended by the World Health Organization.
Relevant changes In 2011, Rwanda’s HPV vaccination programme achieved 93.23% coverage after the first three-dose course of vaccination
among girls in grade six. This was made possible through school-based vaccination and community involvement in identifying girls absent
from or not enrolled in school. A nationwide sensitization campaign preceded delivery of the first dose.
Lessons learnt Through a series of innovative partnerships, Rwanda reduced the historical two-decade gap in vaccine introduction between
high- and low-income countries to just five years. High coverage rates were achieved due to a delivery strategy that built on Rwanda’s
strong vaccination system and human resources framework. Following the GAVI Alliance’s decision to begin financing HPV vaccination,
Rwanda’s example should motivate other countries to explore universal HPV vaccine coverage, although implementation must be tailored
to the local context.

Background
Human papillomavirus (HPV) is a sexually transmitted virus
found in virtually all cases of cervical cancer,1 which kills
275 000 women every year2 and is the biggest contributor to
years of life lost from cancer among women in the developing
world.3 Two HPV vaccines developed in recent years – Merck’s
quadrivalent Gardasil and GlaxoSmithKline’s bivalent Cervarix – have been prequalified by the World Health Organization (WHO) and approved by national governments in many
countries, including Rwanda. These vaccines represent a milestone in biomedical progress towards mitigating the burden of
cervical cancer.4 Vaccination programmes have changed the
landscape of global health drastically by enabling countries to
re-evaluate funding priorities and to invest in prevention when
cost-effective.5 However, 15 to 20 years usually pass between
the introduction of a vaccine in rich and poor countries.6
In recent decades, routine screening programmes have
reduced cervical cancer morbidity and mortality in highincome countries, and this trend is expected to accelerate as
vaccination coverage is scaled up.7 As a result, 77% of new
cases8 and 88% of deaths from the disease now occur in developing countries.2 A five-year delay in introducing the HPV
vaccine to these countries would result in 1.5 to 2 million
preventable deaths.2
Cervical cancer is the most common cancer among
women in Rwanda,9 a country in eastern African with more
than 11 million inhabitants. In 2010, 986 cases of cervical
cancer were diagnosed in Rwanda and 678 women died from
the disease.9 That same year, Rwanda evaluated options for

HPV vaccination rollout and decided to pursue a partnership
with Merck to offer Rwanda’s young girls the opportunity to
receive a life-saving vaccine.
A growing body of scientific literature has emerged in
recent years concerning the use of the HPV vaccine in the
developing world,2,10 but very little evidence on the success
and replicability of nationwide delivery programmes, like
Rwanda’s, has been published. In this article, we describe the
process by which Rwanda became the world’s first low-income
country to provide universal access to the HPV vaccine.

Context
Before 2011, neither cervical cancer screening nor HPV vaccination was available in public health facilities in Rwanda;
only a few private clinics and nongovernmental organizations
offered screening services. Aware that cervical cancer is highly
prevalent in Rwanda, the Ministry of Health considered the
overwhelmingly positive evidence of the effectiveness of the
HPV vaccine to be a call to action.
In April 2009, Rwanda’s First Lady met with senior Merck
officials to initiate advocacy for the HPV vaccine on behalf of
women in Rwanda. An internal technical discussion then occurred between Merck and the Ministry of Health, followed by
conversations with development partners in Rwanda’s health
sector. In April and October 2010, Merck representatives
visited Rwanda to work under the leadership of the Ministry
of Health in developing a national cervical cancer prevention
strategy. Rwanda’s National Strategic Plan for the Prevention,
Control, and Management of Cervical Lesions and Cancer11
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includes screening and vaccination
programmes for women between 35 and
45 years of age, the specifics of which
will be detailed in future articles. A
memorandum of understanding signed
in December 2010 guaranteed Rwanda
three years of vaccinations at no cost
and concessional prices for future doses.
On 26 and 27 April 2011, 93 888
Rwandan girls in primary grade six received their first shot of Gardasil with no
out-of-pocket payment. Data collected
by the Ministry of Health during the
first round of vaccination showed that
94 141 girls were present at school and
that 4 651 girls were either absent or not
enrolled, resulting in a total of 98 792
eligible girls across Rwanda. The programme’s first round achieved 95.04%
coverage, the second 93.90% and the
third, 93.23% (Table 1).

Rwanda’s health sector
Driven by the pursuit of equity, value
and quality, the health sector in Rwanda
has made immense progress in recent
years. Through a decentralization strategy
harnessing Rwanda’s 45 000 community
health workers, the Ministry of Health and
its partners have succeeded in decreasing
the burden of major infectious diseases
and have scaled up disease prevention
programmes efficiently and effectively.
Between 2005 and 2010, Rwanda reduced
malaria incidence by 70% and under-five
mortality by 50%. The country increased
the proportion of infants aged 12–23
months receiving all basic WHO immunizations from 75.2% to 90.1% (with all but
oral polio vaccine coverage rates exceeding 95% in 2010) and assured universal access to antiretroviral therapy.12,13 Rwanda
has also strategically positioned itself to
tackle non-communicable diseases by
building on its successful integration
of infectious disease interventions and
primary health care.14,15

Preparation and
implementation
Three early decisions were crucial to
the success of Rwanda’s HPV vaccine
rollout. First, the Ministry of Health
decided in September 2010 to widen its
technical working group on vaccinations
to include the Ministry of Education,
the Ministry of Gender and Family
Promotion, the Center for Treatment
and Research on AIDS, Tuberculosis,
624

Table 1. Cumulative human papillomavirus vaccination coverage, by vaccination round,
Rwanda, 2011
Coverage

Round 1

Round 2

Girls vaccinated in school, no.
Girls vaccinated outside school, no.
Total no. of girls vaccinated
Cumulative coverage (%)

91 752
2 136
93 888
95.04

89 704
3 066
92 770
93.90

Malaria, and other Epidemics, and
health workers engaged in cancer care.
Multidisciplinary subcommittees were
tasked with identifying cold chain requirements; numbers of girls in and out
of school; nurse and community health
worker training capacity; procurement
and distribution logistics; a budget for
implementation; education and sensitization requirements; and tools for
data collection and social mobilization.
Committees met as often as needed –
often every other day – for about four
months. After the memorandum of
understanding between Merck and the
government of Rwanda was signed, the
following two months were spent devising a strategic plan for rollout preparation, implementation and evaluation.
Concurrently, a nationwide population sensitization campaign was planned
and undertaken months in advance of
vaccination. Speeches by health-care
professionals, local government officials,
clergy and the First Lady were made to
inform parents and children of the new
vaccine. Announcements via newspapers, magazines, radio and television
were included in the communications
strategy. Teachers were trained and encouraged to discuss cervical cancer and
the HPV vaccine with students.
With technical assistance from the
US Centers for Disease Control and
Prevention (CDC) and the International
Center for AIDS Care and Treatment
Programs (ICAP) at Columbia University, Rwanda’s Ministry of Health
conducted a situational analysis in
March 2011 using in-depth interviews
and focus group discussions to assess
the knowledge, attitudes and beliefs
of key stakeholders pertaining to HPV
vaccination. The systematic inclusion of
local leaders, community health workers and teachers in the vaccine delivery
strategy combined with Merck’s in-kind
support to constitute a “public-privatecommunity partnership” for effective
programme implementation specific to
the Rwandan context.

Round 3
88 927
3 180
92 107
93.23

The second major decision was to
partner with the Ministry of Education
to design a school-based strategy to
deliver the standard three doses of the
HPV vaccine. Because 98% of Rwandan
girls attend primary school, 16 implementers felt that the highest coverage
rates could be attained through schools.
Some girls in rural settings are unaware
of their exact ages, and a demonstration
project in Uganda described difficulties
identifying girls through an age-based
programme, 10 so Rwanda elected to
pursue a grade-based strategy.
Third, the technical working group
decided on a multi-phased vaccination strategy spanning three years
(Fig. 1). Every year beginning in 2011,
girls enrolled in primary grade six will
receive the full three-dose course of
HPV vaccine. During the programme’s
second and third years, a “catch-up”
phase targeting girls in the third year of
secondary school will ensure complete
coverage of all pre-adolescent and adolescent girls. In 2014 and beyond, only
primary grade six vaccinations will be
necessary.
Each course of vaccination takes
place over six days: school-based vaccinations across the country during
the first two days, out-of-school girls
are tracked and vaccinated on the third
day, and surveillance of adverse events
is conducted over the remaining three
days. The vaccination is a voluntary
opt-out intervention offered to all girls
in the targeted age groups, regardless of
their school enrolment status. Parents
and guardians had been instructed
through the massive communications
and media campaigns to accompany
their daughters to school on the day
when the first dose was going to be administered. If a parent or guardian did
not come to the school, the girl did not
receive the vaccine. On the days when
vaccines are administered, which the
schools now designate as educational
“health days”, local health-care providers
and teachers discuss topics pertaining to
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Fig. 1. Human papillomavirus vaccination rollout phases, Rwanda, 2011–2014

School year

2011

2012

2013

2014

Primary grade 6
Secondary grade 3

ics and tiered pricing agreements will
most likely drive down vaccine prices in
these settings, as has occurred with the
pneumococcal conjugate vaccine (which
Rwanda was also the first low-income
country to roll out).18

Implications

Table 2. Human papillomavirus vaccination coverage of girls not enrolled in or absent
from school, by vaccination round, Rwanda, 2011
Coverage

Round 1

Round 2

Round 3

Girls vaccinated outside school, no.
Total girls outside school, no.
Coverage of girls outside school (%)

2136
4651
45.93

3066
3679
83.34

3180
3734
85.16

hygiene, nutrition, infectious diseases
and reproductive health.
The vaccination programme technical working group chose to target girls
in primary grade six because most of
them are not yet sexually active but have
reached an appropriate age for initiating sexual education. In Rwanda, the
median age of sexual debut is 20.7 years
and only 2.7% of girls have had sex by
age 15.13

to benefit from the vaccine, Rwanda’s
45 000 community health workers were
mobilized for active tracing of girls who
were enrolled in primary grade six but
absent on a vaccination day, as well as
the small number of girls who were 12
years old but not enrolled in school.
After being identified by community
health workers, girls from both groups
were vaccinated at the local health centre
(Table 2).

Delivery challenges

Resistance

During the first phase of the vaccination
rollout, one of the greatest challenges
faced by implementers was making the
population across the country aware of
eligibility guidelines for the HPV vaccination. Some parents wanted to have
all of their children immunized, and
several female teachers in schools where
the vaccine was delivered also asked to
be vaccinated. Through radio and onsite communication, representatives of
the Ministry of Health acknowledged
the potential benefit of vaccinating all
women at risk for cervical cancer but
explained that this national programme
was intended only for girls before sexual
debut. They also explained that there
would be a “catch-up” phase of HPV vaccination targeting third-year secondary
school students.
Targeted action was taken for the
girls who were sick or otherwise absent
from school on vaccination days, in addition to the small number of girls who
should be in primary grade six but were
not enrolled in school at the time of the
vaccination rollout. To make sure that
no eligible girls missed the opportunity

The HPV vaccine rollout in Rwanda, like
other progressive public health policies
in Africa, has met with some resistance
from the international community. 17
Concerns over the initially high fixed
costs of vaccination have led some to
suggest that a focus on cervical cancer
prevention might detract scarce resources from other more “cost-effective”
child health interventions. Indeed, stateof-the-art health technologies are generally expensive and health ministries face
difficult choices when making budget
allocations. However, Rwanda acted on
its decision to tackle non-communicable
diseases in a systematic way by accepting
Merck’s offer to provide free vaccines
for the first three years of the HPV
vaccination programme. High-level
leaders are committed to ensuring the
long-term integration of a rights-based
cervical cancer prevention, care and
treatment programme into the basic
package of health services. As more
low- and middle-income countries follow Rwanda’s example and confront the
untallied cost of inaction with respect to
cervical cancer, vaccine market dynam-
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A successful nationwide HPV vaccination programme requires a wellestablished vaccine delivery system with
adequate cold chain, transportation, human resources and monitoring capacity.
Collaboration between public and private institutions within the framework
of strong national ownership appears to
be a prerequisite for long-term sustainability. To assure high vaccine uptake,
the health system should have a strong
outreach communication capacity to
clearly address questions on the part of
girls, parents and health workers about
vaccine safety and efficacy and the exclusive focus on young adolescent girls.
Favourable outcomes from HPV
vaccine rollouts and similar initiatives
do not occur by chance; they result
from strong coordination, national
ownership, strategic planning, comprehensive monitoring (especially the
reporting of side-effects and adverse
reactions through teacher training)
and good managerial capacity. Senior
Ministry of Health officials in Rwanda
acknowledged that an emphasis on
health systems strengthening by the
government, The GAVI Alliance, the
President’s Emergency Plan for AIDS
Relief and The Global Fund to Fight
AIDS, Tuberculosis and Malaria was key
to the success of HPV vaccine rollout in
the country.
We are encouraged by the promising initial results of the HPV vaccination programme in Rwanda, which
has attained 93.23% coverage after the
first three-dose course of vaccination.
Rwanda’s example should motivate other
countries to expand their vaccination
programmes to include the HPV vaccine, with due customization according
to their epidemiological, economic,
political, and health system contexts, especially now that the GAVI Alliance has
included the vaccine in its immunization
package and that Merck has lowered the
price to 5 United States dollars per dose
for GAVI Alliance eligible countries.19 ■
Competing interests: None declared.
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ملخص

حتقيق تغطية عالية يف برنامج التمنيع الوطني ضد فريوس الورم احلليمي البرشي يف رواندا

 حقق برنامج التمنيع ضد،2011 التغيات ذات الصلة يف عام
ّر
% 93.23 فريوس الورم احلليمي البرشي يف رواندا تغطية بنسبة
بعد أول دفعة من جرعات اللقاح الثالث بني الفتيات يف الصف
 وحتقق هذا من خالل التمنيع املدريس وإرشاك املجتمع.السادس
املحيل يف حتديد الفتيات املتغيبات عن املدرسة أو غري املسجالت
. وسبق إيتاء اجلرعة األوىل محلة توعية عىل الصعيد الوطني.هبا
الدروس املستفادة خفضت رواندا من خالل سلسلة من الرشاكات
االبتكارية ثغرة العقدين التارخيية بالبدء يف استعامل اللقاح بني
 وتعزى.البلدان مرتفعة ومنخفضة الدخل إىل مخس سنوات فقط
معدالت التغطية العالية التي تم حتقيقها إىل إسرتاتيجية اإليتاء
التي قامت عىل أساس نظام التمنيع وإطار املوارد البرشية القويني
 ويف أعقاب قرار التحالف العاملي من أجل اللقاحات.يف رواندا
،والتمنيع ببدء متويل التمنيع ضد فريوس الورم احلليمي البرشي
ينبغي أن يدفع نموذج رواندا البلدان األخرى إىل بحث التغطية
الشاملة للقاح فريوس الورم احلليمي البرشي عىل الرغم من
.رضورة مالئمة التنفيذ للسياق املحيل

املشكلة مجيع السيدات املصابات برسطان عنق الرحم تقريب ًا
.)HPV( مصابات بعدوى فريوس الورم احلليمي البرشي
 امرأة تتعرض للوفاة من275000  من إمجايل% 88 وتعيش نسبة
 ومتت املوافقة.جراء رسطان عنق الرحم سنو ًيا يف البلدان النامية
، ومع ذلك.عىل لقاحني ملكافحة فريوس الورم احلليمي البرشي
يميل تنفيذ اللقاح يف البلدان منخفضة الدخل إىل التأخر عن التنفيذ
. سنة20  إىل15 يف البلدان مرتفعة الدخل بنحو
 عقدت وزارة الصحة الرواندية رشاكة،2011 األسلوب يف عام
Gardasil مع مريك لتوفري لقاح فريوس الورم احلليمي البرشي
 وشكلت الوزارة “رشاكة بني.جلميع الفتيات من األعامر املناسبة
املجتمع املحيل العام واخلاص” لضامن إيتاء اللقاح بشكل فعال
.وعادل
املواقع املحلية بفضل الرتكيز الوطني القوي عىل تعزيز النظم
 من مجيع الرضع الروانديني% 90  حيصل ما يزيد عن،الصحية
 شهرا عىل مجيع خدمات23 12 الذين ترتاوح أعامرهم بني و
.التمنيع التي تويص هبا منظمة الصحة العاملية

摘要
卢旺达国家人类乳头瘤病毒疫苗接种计划实现高覆盖率
问题 患有宫颈癌的妇女几乎都受到人类乳头瘤病毒
（HPV）感染。每年有 27.5 万名妇女死于宫颈癌，其中
88%生活在发展中国家。两种预防HPV的疫苗已通过审
批。然而，较之高收入国家，低收入国家的疫苗实施情况
往往要落后15 至20 年。
方法 2011 年，卢旺达卫生部与默克公司合作，为所有适
龄女孩提供加德西HPV疫苗。卫生部形成“公私社区合作
伙伴关系”，以确保公平有效地进行疫苗接种。
当地状况 由于国家对强化卫生系统的大力关注，卢旺达所
有12到23个月年龄的婴儿中超过90%接受了世界卫生组织
推荐的所有基本免疫接种。
相关变化 2011 年，卢旺达在对六年级的女孩进行了前

三个疫苗剂量的接种之后， 其HPV疫苗接种计划取得了
93.23%的覆盖率。这是通过基于学校的疫苗接种和社区参
与确定女孩是否缺课或是没有入学得以实现的。在进行第
一剂量接种之前开展了全国性的皮试活动。
经验教训 通过一系列的创新合作伙伴关系，卢旺达把历史
上高收入和低收入国家之间疫苗引进方面二十年的差距缩
短为短短五年。由于在卢旺达强有力的疫苗接种系统和人
力资源框架中建立了实施战略，所以取得了高覆盖率。在
全球疫苗免疫联盟决定开始为HPV免疫筹资之后，尽管实
施方案必须因地制宜，卢旺达的例子仍会调动其他国家探
索普遍的HPV疫苗接种覆盖率。

Résumé
Atteinte d’un niveau de couverture élevé pour le programme national rwandais de vaccination contre le papillomavirus humain
Problème Pratiquement toutes les femmes touchées par le cancer
du col de l’utérus sont infectées par le virus du papillome humain
(VPH). Parmi les 275 000 femmes qui meurent chaque année d’un
cancer du col utérin, 88% d’entre elles vivent dans des pays en voie
de développement. Deux vaccins contre le VPH ont été approuvés.
Toutefois, l’instauration du vaccin dans les pays à revenu faible reste
à la traîne depuis 15 à 20 ans par rapport à sa mise en œuvre dans
les pays à revenu élevé.
Approche En 2011, le ministère de la Santé du Rwanda a créé un
partenariat avec Merck pour offrir le vaccin Gardasil contre le VPH à
toutes les filles d’âge approprié. Le ministère a établi un «partenariat
communautaire public-privé» pour en assurer une délivrance efficace
et équitable.
Environnement local Grâce à un effort national majeur en matière de
renforcement des systèmes de santé, plus de 90% de tous les nourrissons
rwandais âgé de 12 à 23 mois reçoivent l’ensemble des vaccins de base
recommandés par l’Organisation mondiale de la Santé.

626

Changements significatifs En 2011, le programme rwandais de
vaccination contre le VPH a atteint une couverture de 93,23% après la
première cycle de trois doses de vaccin parmi les filles de niveau CM2.
Cela a été rendu possible grâce à une vaccination en milieu scolaire et
à l’implication communautaire dans l’identification des filles absentes
ou non inscrites à l’école. Une campagne nationale de sensibilisation a
précédé l’administration de la première dose.
Leçons tirées Grâce à une série de partenariats novateurs, le Rwanda a
réduit l’écart historique de deux décennies à seulement cinq ans quant
à l’introduction d’un vaccin dans les pays à revenu élevé et faible. Des
taux de couverture élevés ont été atteints grâce à une stratégie de
délivrance basée sur un système de vaccination solide au Rwanda et à
une organisation efficace des ressources humaines. Suite à la décision
de l’Alliance GAVI d’initier le financement de la vaccination contre le
VPH, l’exemple du Rwanda devrait inciter d’autres pays à envisager une
couverture totale du vaccin contre le VPH, bien que la mise en œuvre
doive être adaptée au contexte local.
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Резюме
Широкий охват национальной программой вакцинации против вируса папилломы человека в Руанде
Проблема Практически все женщины, у которых диагностирован
рак шейки матки, инфицированы вирусом папилломы человека
(ВПЧ).Из275 000женщин, которые ежегодно умирают от рака
шейки матки,88%живут в развивающихся странах. Были одобрены
две вакцины против ВПЧ.Тем не менее, страны с низким уровнем
дохода имеет тенденцию отставать в вопросах вакцинации от
стран с высоким доходом на 15-20 лет.
Подход В 2011 году Министерство здравоохранения Руанды в
сотрудничестве с компанией Merck начало программу вакцинации
для всех девочек соответствующего возраста вакциной Гардасил
(Gardasil) против ВПЧ. Министерство создало«государственночастное партнерство», чтобы обеспечить эффективную и равную
вакцинацию.
Местные условия Благодаря пристальному вниманию государства
к укреплению систем здравоохранения более 90% детей в Руанде
получают все основные прививки, рекомендованные Всемирной
организацией здравоохранения.
Осуществленные перемены В 2011 г.программа вакцинации

против ВПЧ в Руанде охватила первой из трех доз вакцины
93,23% девочек, учащихся в шестых классах. Это стало возможным
благодаря школьной вакцинации и участию общественности
в нахождении девочек, которые отсутствовали или вообще
не ходили в школу. Введению первой дозы предшествовала
общенациональная кампания сенсибилизации.
Выводы С помощью ряда инновационных партнерств Руанде
удалось за пять лет сократить исторический разрыв в вопросах
вакцинации размером в два десятилетия, существующий
между странами с высоким и низким уровнем дохода.
Высокие показатели охвата были достигнуты за счет стратегии,
построенной на сильной системе вакцинации в Руанде и
высоком человеческом потенциале. Вслед за решением Альянса
GAVI начать финансирование вакцинации против ВПЧ, пример
Руанды должен мотивировать другие страны рассмотреть
вопрос универсального охвата вакциной против ВПЧ, однако
реализация данных мероприятий должна быть адаптирована к
местным условиям.

Resumen
Cómo alcanzar una cobertura elevada en el programa nacional de vacunación contra el virus del papiloma humano en Rwanda
Situación Casi todas las mujeres que tienen cáncer cervicouterino
están infectadas con el virus del papiloma humano (VPH). De
las 275 000 mujeres que fallecen anualmente debido al cáncer
cervicouterino, el 88% vive en países en desarrollo. Se han aprobado
dos vacunas contra el VPH, no obstante, la implantación de la vacuna en
países de ingresos bajos tiende a quedar entre 15 y 20 años por detrás
de su aplicación en países de ingresos altos.
Enfoque En 2011, el Ministerio de Sanidad de Rwanda se asoció con
Merck para ofrecer la vacuna Gardasil contra el VPH a todas las niñas en la
edad adecuada. El Ministerio formó una «asociación comunitaria públicoprivada» para garantizar un reparto eficaz y equitativo de la misma.
Marco regional Más del 90% de los niños de 12 a 23 meses de edad
en Rwanda ha recibido todas las vacunas básicas recomendadas
por la Organización Mundial de la Salud gracias a los esfuerzos
gubernamentales por mejorar los sistemas sanitarios.
Cambios importantes El programa de vacunación contra el VPH en

Rwanda alcanzó una cobertura del 93,23% entre las niñas de sexto curso
en el año 2011 al cabo de la primera ronda de vacunación con las tres
dosis. Esto fue posible a través de la vacunación escolar y gracias a la
participación de la comunidad para identificar a las niñas que faltaban o
no estaban matriculadas en el colegio. Una campaña de sensibilización
a escala nacional precedió la entrega de la primera dosis.
Lecciones aprendidas A través de una serie de asociaciones
innovadoras, Rwanda redujo a tan solo cinco años la brecha histórica
de dos décadas en cuanto a la introducción de la vacuna entre países
de ingresos altos y bajos. Una estrategia de reparto construida sobre
el sólido sistema de vacunación y el marco de recursos humanos de
Rwanda permitió alcanzar una cobertura elevada. Siguiendo la decisión
de la GAVI Alliance de comenzar a financiar la vacuna contra el VPH,
el ejemplo de Rwanda debería animar a otros países a investigar la
cobertura de la vacuna universal contra el VPH, aunque su aplicación
deberá adaptarse al contexto local.
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